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Background: Experimentally, erythropoietin (EPO) has nephroprotective as well as immunomodulatory properties
when administered after ischemic renal injury. We tested the hypothesis that different doses of recombinant
human EPO administered to patients after cardiac surgery would minimize kidney lesions and the systemic
inflammatory response, thereby decreasing acute kidney injury (AKI) incidence.
Methods: In this double-blinded randomized control study, 80 patients admitted to the ICU post-cardiac surgery
were randomized by computer to receive intravenously isotonic saline (n = 40) versus α-Epoetin (n = 40): either
40000 IU (n = 20) or 20000 IU (n = 20). The study lasted one year. The primary outcome was the change in urinary
NGAL concentration from baseline and 48 h after EPO injection. Creatinine, cystatine C and urinary NGAL levels
were measured on the day of randomization and 2–4 days after EPO injection. To assess acute inflammatory
response, serum cytokines (IL6 and IL8) were measured at randomization and four days after r-HuEPO injection.
Patients and care-takers were blinded for the assignment.
Results: No patient was excluded after randomization. Patient groups did not differ in terms of age, gender,
comorbidities and renal function at randomization. The rate of AKI assessed by AKIN criteria was 22.5% in our
population. EPO treatment did not significantly modify the difference in uNGAl between 48 hours and
randomization compared to placebo [2.5 ng/ml (−17.3; 22.5) vs 0.7 ng/ml (−31.77; 25.15), p = 0.77] and the
incidence of AKI was similar. Inflammatory cytokines levels were not influenced by EPO treatment. Mortality and
hospital stays were similar between the groups and no adverse event was recorded.
Conclusion: In this randomized-controlled trial, α-Epoetin administrated after cardiac surgery, although safe,
demonstrated neither nephroprotective nor anti-inflammatory properties.
Trial registration number: NCT00676234
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Erythropoietin (EPO) is a hematopoietic factor mainly
produced by interstitial fibroblasts in the renal cortex and
outer medulla. In addition to regulating red blood cell
production, this glycoprotein has pleiotropic properties.
Amongst these, cytoprotection has been demonstrated in* Correspondence: Patrick.saudan@hcuge.ch
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distribution, and reproduction in any mediumanimal brain, kidney and liver [1,2]. These effects appear
to be mediated by the presence of receptors that may re-
spond to higher doses of EPO and alter cell survival, pro-
liferation and inflammation [2,3].
Acute kidney injury (AKI) is a frequent complication
in the intensive care unit. Despite decades of research
for a curative treatment, therapy is essentially restricted
to supportive care and mortality remains persistently
high [4]. In experimental models of ischemia-reperfu-
sion, recombinant human EPO (r-HuEPO) injection be-
fore or during the injury appears to protect against acutentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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r-HuEPO, up to 6 hours after a renal ischemic injury,
seems to be nephroprotective in rats [3]. The few data
available in humans do not seem to reproduce this pro-
tective effect [8].
Diagnosis of AKI in the intensive care setting is cur-
rently performed using RIFLE or AKIN criteria [9]. Mor-
tality increases with the AKI stages using these criteria
[10]. In patients undergoing cardiothoracic surgery, AKI
is a relevant complication. However, its incidence is very
variable (between 1 to 30%) according to definitions and
patient’s profile but more frequent in valvular versus
CABG [11] surgeries. Even small increases in creatinine
levels are associated with substantial decrease in 30-day
survival [12]. As both creatinine levels and quantification
of diuresis raise some concern in the ICU setting, novel
biomarkers such as Neutrophil Gelatinase Associated
Lipocalin (NGAL) are studied to identify patients at risk
of developing AKI earlier. The predictive value of these
markers for mortality may also be higher than creatinine,
even at the time of intensive care admission or post-
operatively [13,14]. Urinary NGAL (uNGAL) seems to
be more sensitive than plasmatic dosage. Although, no
consensus definition of AKI exists using these biomar-
kers [15], NGAL detected patients with subclinical AKI
and predicted their mortality despite unchanged serum
creatinine [14]. Additionally, delayed diagnosis of AKI
based on change in creatinine could explain some nega-
tive interventional trials and the absence of effective
therapy in AKI treatment [16].
An inflammatory response is present in most ICU
patients, particularly if they undergo reperfusion injury.
IL6 levels are associated with AKI in postoperative cases
[17,18]. In experimental heart ischemia reperfusion and
in brain ischemia, EPO treatment decreases the systemic
inflammatory response as demonstrated by decreased
levels of IL6, IL8 and TNF-α [19,20].
In this study, we tested the effect of two different
doses of r-HuEPO on renal function administered to
patients early after cardiac surgery. We used uNGAL as
a surrogate of renal function as it has been described to
be an earlier and more sensitive marker of AKI than cre-
atinine. We expected to observe a deeper decrease in
uNGAL levels in the EPO treatment group, which
should be associated with decreasing mortality and
shorter hospital stay. Furthermore, we investigated the
immunomodulatory properties of EPO after cardiac
surgery.
Methods
The study took place in the intensive care unit (ICU) at
the University Hospital in Geneva (Switzerland) in 2008–
2009. Initially, all adults (>18 years old) admitted to the
ICU and at risk for acute kidney injury (mechanicalventilation, sepsis, post-operative state, hemodynamic im-
pairment, previous chronic kidney disease) were screened
for inclusion. Patients were excluded from the study in
case of: malignant hypertension or systolic blood pressure
≥150 mmHg at enrollment, Hb levels ≥120 g/l at
randomization, acute coronary syndrome, pregnancy or
urinary output <600 ml/12 h.
Additionally, according to the request of the national
drug control organ (Swiss Medic), only patients able to
read, ask questions before inclusion and sign a consent
form were eligible for inclusion. Patients unable to under-
stand the information for any reason or in an emergency
situation that prevented prior consent had to be excluded.
Deferred consent or informed consent obtained from
health care proxy could not be used. For this reason, al-
though all patients admitted in the ICU were first sup-
posedly eligible for enrollment, finally only patients having
“elective” cardiac surgery could be asked for consent prior
to randomization and were included in this study. During
surgery, patients were managed according to a published
protocol [21]. The study was approved by the ethical com-
mittee from Geneva University Hospital and registered at
ClinicalTrial.gov (NCT00676234).
Although this was a pilot study, we calculated that 35
patients treated by EPO and 35 controls were necessary
to obtain a 95% power with α <0.05, assuming a between
group difference of 45 ng/ml in our primary endpoint.
Predicting a drop out of 10 patients (5 in each group),
we decided to include 80 patients: 40 would be treated
by EPO and 40 by placebo.
Treatment
In this pilot study we additionally tested 2 different
dosages of EPO in order to estimate a dose-dependent ef-
fect. Patients were randomly allocated to 2 treatment
groups or a control group after cardiac surgery. Group 1
received α-Epoetin: 20’000ui, group 2 α-Epoetin: 40’000ui
and group 3 (control group) isotonic sodium chloride. All
treatments were administered intravenously as a single
dose. EPO was diluted in isotonic sodium chloride. A
randomization code was generated by a computer 1:1:2
and envelopes with allocation were prepared by the quality
of care unit. A nurse from the Nephrology Unit opened
the envelopes and prepared the syringes for injection.
Investigators and patients were blinded to the treatment.
Randomized injection occurred on arrival to the intensive
care unit between 1 and 4 hours after surgery.
Outcome
The primary outcome was the change in urinary NGAL
concentration from baseline and 48 h after r-HuEPO in-
jection. The secondary outcomes were changes in trad-
itional renal function markers (serum creatinine and
cystatine C) and in cytokines levels.
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All patients had baseline renal function (creatinine) mea-
sured at least 24 hours before the surgery. Chronic kid-
ney disease (CKD) was defined as a GFR <60 ml/min/
1.73 m2 using the MDRD equation, or known kidney
disease. Data on comorbidities were collected including
hypertension, diabetes and history of ischemic heart dis-
ease. ICU and hospital stay in days were recorded as well
as mortality and initiation of renal replacement therapy.
Patients were followed for 28 days, looking for possible
complications related to r-HuEPO injection such as cen-
tral or peripheral thrombosis or death. AKI was detected
from ICU admission to the following week using serum
creatinine criteria (AKIN classification). On ICU admis-
sion, blood and urine samples were taken prior to injec-
tion (= randomization time). The same samples were
taken in the morning 48 h and 96 h after the injection.
Serum creatinine and cystatine C were immediately
measured at 3 intervals (randomization, 48 h and 96 h).
Urine was collected and kept at −20° to measure NGAL
at randomization and 48 h. Serum was also kept at −20°
to measure cytokines at randomization and 96 h. Cre-
atinine was measured using the Jaffe technique and
Cystatine C by nephelometry. Rapid NGAL ELISA kit
(Bioport Diagnostics-Gentofte, Denmark) was used to
measure urinary NGAL (uNGAL) [22]. Cytometric bead
array human inflammatory cytokines kit (BD Biosciences
– San Jose, California) was used to measure IL-6 and IL-8.
All samples for NGAL and cytokines measures were pro-
cessed at the same time.
Statistics
Continuous variables were described by mean and stand-
ard deviation when distribution was normal. When not
normally distributed, continuous variables were described
by medians and interquartile ranges (25th-75th). WhenFigure 1 Study flow diagram.distribution changed at different times (randomization,
48 h, 96 h), results were reported as median and inter-
quartile range to homogenize descriptions. Numbers and
percentages described categorical variables. ANOVA or
Kruskall-Wallis test was used to compare continuous vari-
ables between the three randomized groups and chi-
square was used for categorical variables. Paired test
(parametric and non parametric) were performed to assess
changes in creatinine, cystatine C, uNGAl and cytokines
at different intervals (randomization, 48 h, 96 h). Post-hoc
analysis and Bonferroni correction were used when appro-
priate. The interleukins levels were transformed to loga-
rithmic variables for statistics comparisons in order to
achieve a normal distribution.
SPSS17-0 software package (SPSS Inc., Chicago IL)
was used for the analysis.
Results
Over 1 year, 386 patients admitted to ICU were screened
for the study but only 149 met the inclusion criteria.
Non eligibility was mainly due to inability to give
informed consent and Hb ≥ 120 g/l. From the 149 eli-
gible patients, only 80 patients having cardiac surgery,
signed consent forms and were randomized after the
surgery at ICU admission to placebo (n = 40) or EPO
groups (N= 20 in each treatment group). A flow diagram
of the study is depicted in Figure 1. Only 1 patient was
transferred in another hospital at 48 h. Although we
could not have the complete biological follow-up, we
could have the information that he did not develop AKI
and was alive.
Patient’s characteristics and peri-operative interven-
tions are shown in Table 1. Results are described separ-
ately for each EPO treatment (20’000 ui vs 40’000ui) in
order to better analyze an EPO dose-effect. The mean
age was 66.3 ± 14.5 years. There were more men than
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had diabetes (28.8%) or chronic kidney disease (13.8%).
Although many had a history of ischemic heart disease
(41.3%), the majority of surgeries were for valvular re-
placement (61.5%). Only 21.6% of patients had coronary
bypass surgery and 10.8% had at least 2 different inter-
ventions. There were no significant differences between
randomization groups with regards to age, sex, diagnosis
of chronic kidney disease, diabetes, ischemic heart dis-
ease or surgery. Baseline renal function, as assessed by
creatinine levels before surgery, was also similar with a
mean value of 87.8 ± 28.9 μmol/l. We reported some
peri-operative characteristics such as cardiopulmonary
bypass length, inotropic or vasopressor use, necessity of
transfusions and emergency of the intervention that
were all similar between the groups. Some patients in
each group received contrast media before surgery
(n = 7, p > 0.05), but none received nephrotoxic agents
such as aminoglycosides or contrast media after surgery.
Outcomes, AKI and renal function
There were no differences in hemoglobin, creatinine,
cystatine C and urinary NGAL levels between the groups
at randomization (Table 2).
Incidence of AKI was 22.5% in the studied population
(n = 18). Most AKI episodes were stage 1 (n = 15) and
stage 2 (n = 3) and occurred during the first week of ad-
mission. No AKI episodes required renal replacementTable 1 Population and peri-operative intervention character
Variables * All Contr
N= 80 N=4
Population characteristics:
Age in years 66.3 ± 14.5 64.7 ± 1
Sex
Male 56 (70) 27 (67
Female 24 (30) 13 (32
Hypertension 55 (68.8) 26 (6
Diabetes 23 (28.8) 14 (3
Chronic kidney disease 11 (13.8) 6 (15
Ischemic heart disease 33 (41.3) 17 (42
Creatinine baseline μmol/l 86.4 ± 25.5 84.7 ± 2
Intraoperative variables:
Cardiopulmonary bypass min 100 (80–136) 100 (77–
Transfusions administred○ 28 (40) 17 (5
Inotropic agent use 16 (20.3) 6 (15
Vasopressor agent use 18 (22.8) 9 (22.
Urgency of operation 19 (23.8) 7 (17.
*Age and creatinine are expressed as mean ± standard deviation and length of card
Categorical variables are written as numbers of participants and percentages (%).
k p compares the 3 treatment groups.
○ information missing for 10 patients, 6 in the control group:% calculated for a tottherapy. Five patients died early during the follow up
period (mortality 6.25%). ICU stay was usually short
(few hours to 20 days) and hospital stay ranged from 5
to 45 days. No secondary effect could be assigned to
r-HuEPO injection during the follow up and no throm-
botic event was recorded.
Hemoglobin, renal parameters and clinical outcome
according to EPO treatment are presented in Table 2.
R-HuEPO at either of the two doses had no significant
effect on the incidence of AKI. Moreover, r-HuEPO
treatment did not significantly modify the renal function
parameters when compared to control patients as
assessed by the absolute creatinine, cystatin c and urin-
ary NGAL levels at 48 and 96 hours, in each group.
There were no significant differences between the
groups at any time during follow-up with respect to
changes in creatinine, cystatin c and urinary NGAl
levels. Although there was a significant difference in the
change of urinary NGAL levels between the EPO 20’000
and the EPO 40’000 group (p = 0.01), there was no sig-
nificant differences with the placebo group (Figure 2).
We pooled the two EPO doses and confirmed that
r-HuEPO did not significantly modify uNGAL median
levels between 48 hours and randomization: 2.5 ng/ml
(−17.30; 22.50) vs 0.7 ng/ml (−31.78; 25.15); p = 0.767.
Creatinine and cystatin C levels changed equally in both
groups at all time points. Incidence of AKI during follow
up using AKIN criteria was similar in placebo and rh-istics according to treatment group
ol EPO 20’000ui EPO 40’000ui P||
0 N=20 N=20
4.7 68.9 ± 12.0 66.5 ± 16.5 0.56
.5) 16 (80) 13 (65) 0.52
.5) 4 (20) 7 (35)
5) 17 (85) 12 (60) 0.18
5) 5 (25) 4 (20) 0.44
) 2 (10) 3 (15) 0.85
.5) 9 (45) 7 (35) 0.79
6.4 92.5 ± 26.1 86.7 ± 24.0 0.79
120) 96 (77.5-144) 110 (83–143) 0.58
0) 6 (33.3) 5 (27.8) 0.24
) 4 (21.1) 6 (30) 0.39
5) 4 (21.1) 5 (25) 0.96
5) 5(25) 7 (35) 0.32
iopulmonary bypass as median (25th-75thpercentiles).
al of 70 patients.
Table 2 Patients’ evolution during follow-up: hemoglobin, renal biomarkers and clinical outcomes
Variables Control EPO 20’000ui EPO 40’000ui P*
Median (25th-75th percentiles) N= 40 N=20 N=20
Hemoglobin R g/l 97.5 (87.5-105.8) 100.5 (92.3-107) 98 (85–107) 0.41
Hemoglobin last g/l 100.5 (96.3-113.8) 100.0 (93–109) 101.5 (90.8-114.8) 0.69
Renal biomarkers
Creatinine R μmol/l 78 (61–98) 94 (74.5-102) 91.5 (67.8-114.3) 0.29
Creatinine 48 h μmol/l 79 (65.8-88.8) 78 (62–98) 82.5 (66–114.5) 0.23
Creatinine 96 h μmol/l 77.5 (63.3-85.8) 75 (65–92) 87 (72.8-100.8) 0.53
Cystatine C Rmg/l 1.1 (0.9-1.4) 1.2 (1.1-1.5) 1.2 (1.0-1.4) 0.60
Cystatine C 48 h - mg/l 1.2 (1.1-1.4) 1.3 (1.1-1.6) 1.3 (1.1-1.6) 0.25
Cystatine C 96 h mg/l 1.3 (1.1-1.4) 1.2 (1.1-1.5) 1.3 (1.1-1.7) 0.80
Urinary Ngal R ng/ml 21 (5.7-44.3) 43.3 (18.3-62.9) 11 (0–76) 0.18
Urinary Ngal 48 h ng/ml 26.8 (12–46.7) 15.7 (2.6-39) 26 (6.2-58.8) 0.47
Clinical outcomes
Hospital stay in days 14.5 (11–21.8) 16.5 (10.8- 26.8) 15.5 (10.3-22.5) 0.96
ICU stay in days 1 (1–3) 2.5 (1.3- 5) 1 (1–3.8) 0.07
Acute Kidney Injury ¤ 7 (17.5%) 5 (25%) 6 (30%) 0.53
Death 2 (5%) 1 (5%) 2 (10%) 0.74
*p compares the 3 treatment groups.
R: randomization. 48 h: 48 hours after randomization. 96 h: 96 hours after randomization. ICU: Intensive care Unit.
¤ In stage 1: n = 15; in stage 2: n = 3 (n = 2 in EPO 40’000 and n= 1 in EPO 20’000 groups).
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lar during follow up in both groups. R-HuEPO did not
influence outcomes such as death, length of hospital or
ICU stays.
Hemoglobin levels, at randomization and at hospital
discharge, were the same in the 3 groups.
Patients diagnosed with AKI during follow-up
presented with significantly higher creatinine, cystatine
C and urinary NGAL levels at ICU admission
(randomization time) as shown in Table 3. The levels of
all renal biomarkers remained higher during the 48 h-
96 h period in patients with AKI.
Similarly, the five patients that died during follow-up
demonstrated higher levels of both cystatine C (1.76
+/−0.47 mg/l vs. 1.23+/−0.34 mg/l, p = 0.004) and urin-
ary NGAL (103.2 ng/ml vs. 22.2 ng/ml, p = 0.004) at
randomization, whereas creatinine levels were not statisti-
cally different (86.6± 28.8 μmol/l vs. 102.3 ± 33.3 μmol/l,
p = 0.24).
Evolution of plasma IL6 and IL8 in the treatment groups
IL6 and IL8 levels were similar at randomization be-
tween placebo and EPO treated patients. We obtained
the same results when the three groups were analyzed
separately (Table 4). The levels of these cytokines signifi-
cantly decreased during follow-up in all groups. No dif-
ference was observed on the levels of these cytokines at
either time-point after r-HuEPO treatments. Further-
more, IL6 and IL8 levels at randomization were similarin all patients regardless of AKI (Figure 3), whereas IL6
levels at 96 hours were significantly higher in patients
with AKI [124.5 (51.7-213.9)pgl/ml vs 33.8 (19.8-138.9)
pg/ml, p = 0.027] (Figure 3) IL6 levels at randomization
were much higher in patients who died [947 (351.7-
1311.1) vs 198 (142.7-283.2), p = 0.007], while IL8 levels
were slightly higher [197.1 (159.9-189.1) vs 87.9 (49.8-
137.5), p = 0.046].
Discussion
R-HuEPO treatment has renoprotective properties in ex-
perimental ischemic renal injury when given before, dur-
ing or even after the injury [5-7]. The effect of r-HuEPO
on prevention and treatment of AKI in patients is still
very controversial. In our study, we gave r-HuEPO
shortly after cardiac surgery which was inefficient in pre-
venting mild forms of AKI, independent of the dose
used. Moreover, EPO did not modify NGAL urinary
levels, nor did it reduce hospital stay and mortality. This
contrasts with a recent study [23] where erythropoietin
given at the time of operation was efficient in preventing
acute kidney injury, reducing ICU stays and decreasing
mortality in cardiac surgery patients. However, timing of
administration and type of r-HuEPO (epoetin-beta) dif-
fered from our study protocol. Another interventional
study in high risk ICU patients, including patients with
miscellaneous causes of kidney injuries, demonstrated
that EPO was ineffective at preventing mild or severe
AKI and did not modify mortality and need for dialysis
Figure 2 Changes in renal biomarkers at randomization, 48 h
(R-48 h) and 96 h (R-96 h) according to treatment group. Panels
a, b and c represent creatinine, cystatine C and urinary NGAL
differences, respectively (*outliers). NS: non significant.
Table 3 Levels of renal biomarkers during follow up
classified by diagnosis of AKI
Variables* No AKI AKI P
N=62 N=18
Creatinine R μmol/l 79.4 ± 19.8 116 ± 39.9 =0.001
Creatinine 48 h μmol/l 74.0 ± 19.7 142.1 ± 50.8 <0.001
Creatinine 96 h μmol/l 74.1 ± 18.1 129.7 ± 46.4 <0.001
Cystatin C R mg/l 1.14 ± 0 .24 1.67 ± 0.44 <0.001
Cystatin C 48 h mg/l 1.20 ± 0.27 1.73 ± 0.36 <0.001
Cystatin C 96 h mg/l 1.20 ± 0.24 1.90 ± 0.49 <0.001
uNGAL R ng/ml 18.9 (0–43.5) 57.6 (26.5-138.8) <0.001
uNGAL 48 h ng/ml 17.4 (5.8-40.9) 40.2 (21.1-102.6) 0.009
R: randomization. 48 h: 48 hours after randomization. 96 h: 96 hours after
randomization. AKI: acute kidney injury.
*Cystatine C is expressed as mean ± standard deviation. uNGAL is expressed as
median and (25th-75th percentiles).
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patients were selected based on the rise in tubular bio-
markers, and therefore were probably also treated after
the onset of renal injury. In kidney transplant recipients,
EPO administered prior to transplantation did not de-
crease the rate of delayed graft function [25]. Altogether,
these studies show that erythropoietin may have some
beneficial effect in human AKI when given before the is-
chemic injury. However, even an early post injury treat-
ment, in opposition to what is observed in rodents,
appears ineffective. This would limit the applicability of
EPO treatment post-intervention in prevention of AKI
in ICU patients or should lead to a more thorough iden-
tification of high-risk patients before intervention or be-
fore other procedures with a renal risk such as contrast
media administration. Nevertheless, these conclusions
are supported only by one positive monocentric study
[23] and more data are necessary. The ongoing EPO-TBI
study (NCT 00987454) may provide an answer to this
question. This study aims to include 606 patients having
traumatic brain injury to evaluate EPO for brain protec-
tion but renal biomarkers will be also analyzed [8]. Fi-
nally, a study testing the effect of r-HuEPO using a
scoring system identifying high-risk patients would be
desirable.
Change in urinary NGAL levels was a primary out-
come and pooled data showed no effect of r-HuEPO on
uNGAL levels compared to placebo during the observa-
tion time. We observed that α-Epoetin 20’000ui had a
tendency toward decreasing urinary NGAL in compari-
son to the higher dose, but not in comparison to pla-
cebo. The difference between high and low doses of
r-HuEPO has not been described previously and we do
not have a clear explanation for this result. This could
be a statistical difference due to the small sample as clin-
ically relevant parameters (death, length of stay, ICU
Table 4 Levels of interleukins during follow-up
Variables * All Control EPO 20’000 EPO 40’000 P||
pg/ml N=80 N=40 N=20 N=20
IL-6 R 207.7 (144.1-301.2) 177.8 (104.7-351.4) 229.5 (159.8-342.9) 250 (177.8-280.3) 0.54
IL-6 96 h 51.7 (20.5-143.4) 48.3 (18.9-139.9) 129.6 (20.5-248.6) 50.7 (27.7-135.3) 0.46
IL-8 R 98.4 (50.4-154.3) 98.4 (46.3-142.8) 105.4 (56–220.4) 96.6 (52.0-148.9) 0.81
IL-8 96 h 40.1 (21.9-124.4) 41.4 (22,5-121.1) 62.3 (20.9-172.4) 30.9 (17.7-104.7) 0.40
*Expressed as median (25th-75th percentiles).
R: randomization. 96 h: 96 hours after randomization.
k p compares the 3 treatment groups using log transformation.
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groups, although we cannot formally exclude a dose-
dependent effect. The choice of NGAL levels as a pri-
mary outcome was made on the presumption of a better
sensitivity of this test for AKI detection. However, estab-
lishing the sensitivity of NGAL is difficult given the lack
of current gold standard for AKI diagnosis and we be-
lieve that NGAL levels over time may be of interest
given its prognostic value for outcome [26]. In our
patients we only measured NGAL, IL6, IL8 and cystatine
C at ICU admission. Baseline values were not available.
However, in patients suffering from AKI, both NGAL
and cystatine C levels were significantly higher at admis-
sion than in non-AKI patients. Similar observations were
made in patients that died during the observation
period. Despite the low number of events, this tends to
confirm that NGAL and cystatine C levels at admission
(3–4 hours after surgery) are more valuable than creatin-
ine levels in predicting AKI and mortality, as shown in
other studies [13,14,27].Figure 3 Interleukin levels over time in presence or absence of AKI. P
96 hours, respectively, in patient with and without AKI (*outliers). p cIn our study, the incidence of AKI (all stages) was
22.5%, but only three patients suffered from stage 2 AKI
and no patient required dialysis. The incidence of severe
AKI was low despite the high prevalence of diabetes and
CKD and that most of the patients underwent valvular
replacement. This may be related to the inclusion of
elective patients only due to strict exclusion criteria. Fur-
thermore no nephrotoxic drug was prescribed nor was a
contrast agent administered during the observation
period that could have increased the rate of renal events.
Although 7 patients received contrast medium before
surgery they did not have a higher rate of AKI. Recent
observations also establish a lower incidence of severe
AKI after cardiac surgery than previously reported, des-
pite a remaining important repercussion of low grade
AKI on mortality and costs [28]. This may be due to im-
provement in anesthetic care and surgical techniques.
Given this limitation, we cannot demonstrate a protect-
ive effect of r-HuEPO on severe AKI after cardiac sur-
gery. However, our study demonstrates that stage 1 AKI,anel a and panel b represent IL6 and IL 8 at randomization and
ompares groups using log transformation.
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correlated to mortality, length of stay and costs, is not
prevented by r-HuEPO treatment.
Erythropoietin has been shown to have immunomodu-
latory effects [19,20,29]. In this study, IL6 and IL8 levels
were elevated postoperatively and decreased thereafter.
Administration of r-HuEPO shortly after surgery did not
modify the plasma profile of these cytokines. As IL6 is
emerging as a predictive factor for acute kidney injury
and adverse post-operative outcomes [17,30], the ab-
sence of a beneficial effect of EPO on its levels parallels
the unchanged incidence of acute kidney injury and
mortality. This, together with the absence of a protective
effect on renal function, does not support the use of r-
HuEPO to decrease the anti-inflammatory response.
Our study has several limitations. First the number of
events was quite small and for that reason the study
may be underpowered even with the use of a sensitive
primary outcome measure of change in urinary NGAL
levels since the standard deviation of uNGAl was higher
than expected. Secondly, we cannot exclude the pres-
ence of elevated NGAL levels before randomization, es-
pecially in patients with chronic kidney disease or
diabetes, as blood was not taken from patients prior to
surgery. Nevertheless diabetic patients did not show
increased levels of uNGAL at randomization. As for
CKD patients, data are difficult to analyze because of a
small sample size. In each treatment group, the uNGAL
level was higher at randomization in patients with
CKD but the change in uNGAL level at 48 h and
randomization or between treatment groups was not sig-
nificantly different. Finally, we did not correct uNGAL
for urinary creatinine levels, as this correction did not
modify sensitivity of uNGAL in similar settings [27].
Nevertheless, this study is one of the few randomized
studies studying EPO effects on renal function and is the
only one testing the effect of EPO on inflammatory mar-
kers such as cytokines.
Conclusion
In conclusion, administration of two different doses of
α-Epoetin:to adult patients after cardiac surgery did nei-
ther decrease markers of renal injury or renal function
such as urinary NGAL, cystatine C and creatinine, nor
modify the incidence of stages 1 and 2 AKI. In addition,
EPO did not modify pro-inflammatory cytokine levels.
Erythropoietin administered after an ischemic injury is
probably ineffective in patients to prevent low stage AKI
and improve survival.
Abbreviations
EPO: Erythropoeitin; r-HuEPO: Recombinant human erythropoietin; AKI: Acute
kidney injury; NGAL: Neutrophil gelatinase-associated lipocalin;
uNGAL: Urinary Neutrophil gelatinase-associated lipocalin; CKD: Chronic
kidney disease; ICU: Intensive care unit.Competing interests
The authors declare that they have no competing interest.
Authors’ contributions
SdS and BP collected the data, analyzed the results and wrote the
manuscript. LW collected the data. JP and JAR contributed to designing the
study and recruiting the patients. PYM and PS designed the study, collected
the data and revised the manuscript. All authors read and approved the final
manuscript.
Acknowledgements
Janssen-Cilag provided the r-HuEPO in the active treatment arm and
covered the cost for NGAL measurements. They had no role in study design,
data collection, statistical analysis or writing of the manuscript. The authors
had full access to all data and had final responsibility to submit for
publication.
Results of this study have been previously reported in abstract form (ASN
2009-ASN2010).





1Service of Nephrology, Department of Medical Specialties, Geneva
University Hospitals, Rue Gabrielle-Perret Gentil 4, 1211, Geneva, Switzerland.
2Department of internal medicine, Geneva University Hospitals, Geneva,
Switzerland. 3Service of General Intensive Care, Department of
Anesthesiology, Geneva University Hospitals, Geneva, Switzerland.
Received: 10 May 2012 Accepted: 17 September 2012
Published: 3 October 2012
References
1. Arcasoy MO: The non-haematopoietic biological effects of erythropoietin.
Br J Haematol 2008, 141(1):14–31.
2. Brines M: The therapeutic potential of erythropoiesis-stimulating agents
for tissue protection: a tale of two receptors. Blood Purif 2010, 29(2):86–92.
3. Johnson DW, Pat B, Vesey DA, Guan Z, Endre Z, Gobe GC: Delayed
administration of darbepoetin or erythropoietin protects against
ischemic acute renal injury and failure. Kidney Int 2006, 69(10):1806–1813.
4. Uchino S, Kellum JA, Bellomo R, et al: Acute renal failure in critically ill
patients: a multinational, multicenter study. JAMA 2005, 294(7):813–818.
5. Vesey DA, Cheung C, Pat B, Endre Z, Gobe G, Johnson DW: Erythropoietin
protects against ischaemic acute renal injury. Nephrol Dial Transplant
2004, 19(2):348–355.
6. Sharples EJ, Patel N, Brown P, et al: Erythropoietin protects the kidney
against the injury and dysfunction caused by ischemia-reperfusion. J Am
Soc Nephrol 2004, 15(8):2115–2124.
7. Yang CW, Li C, Jung JY, et al: Preconditioning with erythropoietin protects
against subsequent ischemia-reperfusion injury in rat kidney. FASEB J
2003, 17(12):1754–1755.
8. Moore E, Bellomo R: Erythropoietin (EPO) in acute kidney injury. Ann
Intensive Care 2011, 1(1):3.
9. Mehta RL, Kellum JA, Shah SV, et al: Acute Kidney Injury Network: report
of an initiative to improve outcomes in acute kidney injury. Crit Care
2007, 11(2):R31.
10. Ricci Z, Cruz D, Ronco C: The RIFLE classification for acute kidney injury
definition. Am J Surg 2009, 198(1):152–153.
11. Mariscalco G, Lorusso R, Dominici C, Renzulli A, Sala A: Acute kidney injury:
a relevant complication after cardiac surgery. Ann Thorac Surg 2011,
92(4):1539–1547.
12. Lassnigg A, Schmidlin D, Mouhieddine M, et al: Minimal changes of serum
creatinine predict prognosis in patients after cardiothoracic surgery: a
prospective cohort study. J Am Soc Nephrol 2004, 15(6):1597–1605.
13. Haase M, Bellomo R, Devarajan P, et al: Novel biomarkers early predict the
severity of acute kidney injury after cardiac surgery in adults. Ann Thorac
Surg 2009, 88(1):124–130.
14. Haase M, Devarajan P, Haase-Fielitz A, et al: The outcome of neutrophil
gelatinase-associated lipocalin-positive subclinical acute kidney injury: a
de Seigneux et al. BMC Nephrology 2012, 13:132 Page 9 of 9
http://www.biomedcentral.com/1471-2369/13/132multicenter pooled analysis of prospective studies. J Am Coll Cardiol 2011,
57(17):1752–1761.
15. Koyner JL, Vaidya VS, Bennett MR, et al: Urinary biomarkers in the clinical
prognosis and early detection of acute kidney injury. Clin J Am Soc
Nephrol 2010, 5(12):2154–2165.
16. Park M, Coca SG, Nigwekar SU, Garg AX, Garwood S, Parikh CR: Prevention
and treatment of acute kidney injury in patients undergoing cardiac
surgery: a systematic review. Am J Nephrol 2010, 31(5):408–418.
17. Chawla LS, Seneff MG, Nelson DR, et al: Elevated plasma concentrations of
IL-6 and elevated APACHE II score predict acute kidney injury in patients
with severe sepsis. Clin J Am Soc Nephrol 2007, 2(1):22–30.
18. Gueret G, Lion F, Guriec N, et al: Acute renal dysfunction after cardiac
surgery with cardiopulmonary bypass is associated with plasmatic IL6
increase. Cytokine 2009, 45(2):92–98.
19. Bian XX, Yuan XS, Qi CP: Effect of recombinant human erythropoietin on
serum S100B protein and interleukin-6 levels after traumatic brain injury
in the rat. Neurol Med Chir (Tokyo) 2010, 50(5):361–366.
20. Shen Y, Wang Y, Li D, et al: Recombinant human erythropoietin
pretreatment attenuates heart ischemia-reperfusion injury in rats by
suppressing the systemic inflammatory response. Transplant Proc 2010,
42(5):1595–1597.
21. Licker M, Diaper J, Cartier V, et al: Clinical Review: Management of
weaning from cardiopulmonary bypass after cardiac surgery. Ann Card
Anaesth 2012, 15(3):206–223.
22. Pedersen KR, Ravn HB, Hjortdal VE, Norregaard R, Povlsen JV: Neutrophil
gelatinase-associated lipocalin (NGAL): validation of commercially
available ELISA. Scand J Clin Lab Invest 2010, 70(5):374–382.
23. Song YR, Lee T, You SJ, et al: Prevention of acute kidney injury by
erythropoietin in patients undergoing coronary artery bypass grafting: a
pilot study. Am J Nephrol 2009, 30(3):253–260.
24. Endre ZH, Walker RJ, Pickering JW, et al: Early intervention with
erythropoietin does not affect the outcome of acute kidney injury
(the EARLYARF trial). Kidney Int 2010, 77(11):1020–1030.
25. Martinez F, Kamar N, Pallet N, et al: High dose epoetin beta in the first
weeks following renal transplantation and delayed graft function:
Results of the Neo-PDGF Study. Am J Transplant 2010, 10(7):1695–1700.
26. Hall IE, Coca SG, Perazella MA, et al: Risk of Poor Outcomes with Novel
and Traditional Biomarkers at Clinical AKI Diagnosis. Clin J Am Soc
Nephrol 2011, 6(12):2740–2749.
27. Mishra J, Dent C, Tarabishi R, et al: Neutrophil gelatinase-associated
lipocalin (NGAL) as a biomarker for acute renal injury after cardiac
surgery. Lancet 2005, 365(9466):1231–1238.
28. Dasta JF, Kane-Gill SL, Durtschi AJ, Pathak DS, Kellum JA: Costs and
outcomes of acute kidney injury (AKI) following cardiac surgery. Nephrol
Dial Transplant 2008, 23(6):1970–1974.
29. Solling C, Christensen AT, Krag S, et al: Erythropoietin administration is
associated with short-term improvement in glomerular filtration rate
after ischemia-reperfusion injury. Acta Anaesthesiol Scand 2011,
55(2):185–195.
30. Liu KD, Altmann C, Smits G, et al: Serum interleukin-6 and interleukin-8
are early biomarkers of acute kidney injury and predict prolonged
mechanical ventilation in children undergoing cardiac surgery: a
case–control study. Crit Care 2009, 13(4):R104.
doi:10.1186/1471-2369-13-132
Cite this article as: de Seigneux et al.: Epoetin administrated after
cardiac surgery: effects on renal function and inflammation in a
randomized controlled study. BMC Nephrology 2012 13:132.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
